Dehm S - Search Results

1

Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hessein M, Hsing M, Singh K, LeBlanc E, Dehm S, Tomlinson Guns ES, Cherkasov A, Rennie PS. Dalal K, et al. Among authors: dehm s. J Biol Chem. 2014 Sep 19;289(38):26417-26429. doi: 10.1074/jbc.M114.553818. Epub 2014 Aug 1. J Biol Chem. 2014. PMID: 25086042 Free PMC article.

2

Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies.

Miller CD, Lozada JR, Zorko NA, Elliott A, Makovec A, Radovich M, Heath EI, Agarwal N, Mckay RR, Garje R, Bastos BR, Hoon DSB, Orme JJ, Sartor O, VanderWalde A, Nabhan C, Sledge G, Shenderov E, Dehm SM, Lou E, Miller JS, Hwang JH, Antonarakis ES. Miller CD, et al. Among authors: dehm sm. Cancer Res Commun. 2024 May 30;4(5):1369-1379. doi: 10.1158/2767-9764.CRC-23-0546. Cancer Res Commun. 2024. PMID: 38709075 Free PMC article.

3

Molecular regulation of androgen action in prostate cancer.

Dehm SM, Tindall DJ. Dehm SM, et al. J Cell Biochem. 2006 Oct 1;99(2):333-44. doi: 10.1002/jcb.20794. J Cell Biochem. 2006. PMID: 16518832 Review.

4

Ligand-independent androgen receptor activity is activation function-2-independent and resistant to antiandrogens in androgen refractory prostate cancer cells.

Dehm SM, Tindall DJ. Dehm SM, et al. J Biol Chem. 2006 Sep 22;281(38):27882-93. doi: 10.1074/jbc.M605002200. Epub 2006 Jul 25. J Biol Chem. 2006. PMID: 16870607 Free article.

5

Androgen receptor structural and functional elements: role and regulation in prostate cancer.

Dehm SM, Tindall DJ. Dehm SM, et al. Mol Endocrinol. 2007 Dec;21(12):2855-63. doi: 10.1210/me.2007-0223. Epub 2007 Jul 17. Mol Endocrinol. 2007. PMID: 17636035 Review.

6

Selective role of an NH2-terminal WxxLF motif for aberrant androgen receptor activation in androgen depletion independent prostate cancer cells.

Dehm SM, Regan KM, Schmidt LJ, Tindall DJ. Dehm SM, et al. Cancer Res. 2007 Oct 15;67(20):10067-77. doi: 10.1158/0008-5472.CAN-07-1267. Cancer Res. 2007. PMID: 17942941

7

Intragenic rearrangement and altered RNA splicing of the androgen receptor in a cell-based model of prostate cancer progression.

Li Y, Alsagabi M, Fan D, Bova GS, Tewfik AH, Dehm SM. Li Y, et al. Cancer Res. 2011 Mar 15;71(6):2108-17. doi: 10.1158/0008-5472.CAN-10-1998. Epub 2011 Jan 19. Cancer Res. 2011. PMID: 21248069 Free PMC article.

8

Alternatively spliced androgen receptor variants.

Dehm SM, Tindall DJ. Dehm SM, et al. Endocr Relat Cancer. 2011 Sep 20;18(5):R183-96. doi: 10.1530/ERC-11-0141. Print 2011 Oct. Endocr Relat Cancer. 2011. PMID: 21778211 Free PMC article. Review.

9

AR intragenic deletions linked to androgen receptor splice variant expression and activity in models of prostate cancer progression.

Li Y, Hwang TH, Oseth LA, Hauge A, Vessella RL, Schmechel SC, Hirsch B, Beckman KB, Silverstein KA, Dehm SM. Li Y, et al. Among authors: dehm sm. Oncogene. 2012 Nov 8;31(45):4759-67. doi: 10.1038/onc.2011.637. Epub 2012 Jan 23. Oncogene. 2012. PMID: 22266865 Free PMC article.

10

Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal.

Chan SC, Li Y, Dehm SM. Chan SC, et al. J Biol Chem. 2012 Jun 1;287(23):19736-49. doi: 10.1074/jbc.M112.352930. Epub 2012 Apr 24. J Biol Chem. 2012. PMID: 22532567 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

140 results

Search Page

Filters